Status:
TERMINATED
Docetaxel, Carboplatin, and Bevacizumab in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery
Lead Sponsor:
University of California, San Francisco
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
RATIONALE: Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoc...
Detailed Description
OBJECTIVES: Primary * Determine the clinical response rate in patients with stage IB-IIIA non-small cell lung cancer treated with neoadjuvant docetaxel, carboplatin, and bevacizumab. Secondary * D...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Histologically confirmed non-small cell lung cancer
- No squamous cell carcinoma
- No histology in close proximity to a major vessel
- Resectable stage IB-IIIA disease
- No CNS or brain metastases
- PATIENT CHARACTERISTICS:
- ECOG performance status 0-1
- Absolute neutrophil count ≥ 1,500/mm\^3
- Platelet count ≥ 100,000/mm\^3
- Hemoglobin ≥ 8.0 g/dL
- Bilirubin normal
- Creatinine ≤ 1.5 mg/dL
- Urine protein:creatinine \< 1.0
- Alkaline phosphatase (AP), AST, and ALT must meet 1 of the following criteria:
- AP normal AND AST and ALT ≤ 5 times upper limit of normal (ULN)
- AP ≤ 2.5 times ULN AND AST and ALT ≤ 1.5 times ULN
- AP ≤ 5 times ULN AND AST and ALT normal
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for at least 3 months after completion of study treatment
- Adequate pulmonary and cardiovascular function to tolerate surgical resection
- No cavitation or history of hemoptysis (i.e., bright red blood ≥ ½ teaspoon)
- No existing peripheral neuropathy ≥ grade 1
- No known history of severe hypersensitivity reaction to drugs formulated with polysorbate 80
- No history of serious systemic disease, including any of the following:
- Myocardial infarction within the past 6 months
- Uncontrolled hypertension (i.e., blood pressure \> 150/110 mm Hg on medication)
- Unstable angina
- New York Heart Association class II-IV congestive heart failure
- Unstable symptomatic arrhythmia requiring medication
- Patients with chronic atrial arrhythmia (i.e., atrial fibrillation or paroxysmal supraventricular tachycardia) are eligible
- Clinically significant peripheral vascular disease (i.e., grade II or higher)
- No history of significant neurological or psychiatric condition
- No known active infection within the past 14 days
- No serious, nonhealing wound, ulcer, or bone fracture
- No evidence of bleeding diathesis or coagulopathy
- No stroke within the past 6 months
- No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days
- No other serious illness or medical condition
- No active infection
- No other currently active malignancy except nonmelanoma skin cancer
- Malignancies for which therapy has been completed and are considered to have ≤ 30% chance of risk of relapse are not considered active
- PRIOR CONCURRENT THERAPY:
- No prior chemotherapy or VEGF inhibitor
- No prior (i.e., within the past 4 weeks), concurrent, or anticipated participation in another experimental drug study except a Genentech-sponsored bevacizumab cancer study
- No major surgical procedure, open biopsy, or significant traumatic injury within the past 28 days
- No anticipation for major surgical procedure during study treatment
- No fine-needle aspiration or core biopsy within 7 days prior to study entry
- No concurrent full-dose anticoagulation
- No other concurrent chemotherapy, immunotherapy, radiotherapy, or investigational therapy for this cancer
Exclusion
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2007
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT00293332
Start Date
December 1 2005
End Date
April 1 2007
Last Update
February 9 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UCSF Comprehensive Cancer Center
San Francisco, California, United States, 94115